Cart (0 Items)
Your cart is currently empty.
View ProductsStart an oncology antibody project Explore the full workflow
Immuno-oncology antibody development
End-to-end partner to accelerate your oncology antibody program
From complex oncology targets to advanced antibody formats, ProteoGenix combines fully human discovery platforms, cancer-focused libraries, AI-designed antibody candidates and wet-lab validation to help you advance therapeutic antibody programs with confidence.
-
Complex targets
Neoantigens • Immune checkpoints • pMHC
-
Fully human antibodies
Cancer phage display • Single B cell • De novo generation • Hybridoma
-
Advanced oncology formats
CAR-T • Bispecifics • ADCs • VHHs
Integrated end-to-end workflow
ProteoGenix, your partner from antigen design to bioproduction
ProteoGenix supports immuno-oncology antibody programs across the full early development path. Our integrated approach uses AI as an accelerator within the antibody development workflow, helping generate and prioritize candidate sequences faster before confirming their potential through in-house wet-lab validation. By combining AI-powered design, experimental expertise, and bioproduction capabilities under one roof, we accelerate candidate exploration, reduce development timelines, and limit reproducibility issues linked to multi-vendor handoffs.
Complex immuno-oncology target expertise
Solving complex immuno-oncology targets thanks to ProteoGenix
ProteoGenix designs tailored strategies to improve the chances of identifying relevant binders against the difficult targets, including programs aiming to access intracellular tumor antigens through peptide-MHC recognition.
95%
Success Rate
For complex target antibody discovery
1st
First human phage display library
Access to proprietary cancer and autoimmune human phage display libraries
3+
Unique Binders
Guaranteed for your antibody discovery program
100%
Full Ownership
Complete ownership of all generated antibody sequences
Immuno-oncology targets we support
-
Neoantigene
Access intracellular tumor targets through neoantigen-derived peptide-MHC antibody discovery, with at least 3 unique binders guaranteed and dedicated support with Mhc-peptide complex antibody service, TCR-like phage display and neopeptide synthesis.
-
Immune checkpoint
Support next-generation immuno-oncology programs with functional checkpoint antibodies generated against targets in native membrane conformation, supported by precise AI-powered epitope mapping.
Discover high-affinity antibodies with 4 discovery platforms
ProteoGenix offers multiple complementary discovery routes, so the strategy always fits your target, timeline, and downstream application rather than the other way around.
High affinity: 10⁻⁹–10⁻¹² M • Your sequence in 2–3 days • Minimum 3 binders guaranteed • No win, no fee guarantee
-
De Novo AI Antibody Design
AI-guided antibody design that generates and prioritizes candidate sequences in silico before wet-lab validation. Expands the sequence space and accelerates discovery against challenging targets.
-
Phage Display Services
In vitro selection from large libraries, including the world’s first cancer patient-derived library (86 patients, 18 indications). Generates fully human, tumor-specific antibodies against the toughest targets in just 4 weeks — no immunization needed.
→ Explore our Patient-Derived Cancer Antibody Library for Phage Display
-
Custom Hybridoma Development
The proven route for robust monoclonal antibodies via animal immunization. Ideal for stable, high-affinity clones and large candidate panels against well-behaved antigens.
→ Explore custom hybridoma development
-
Single B-Cell Antibody Services
Direct screening of individual B cells, preserving the natural VH/VL pairing. A fast route to rare, high-affinity, natively paired candidates with full sequence information.
→ Explore single B-cell antibody service
Antibody formats tailored to your immuno-oncology program
ProteoGenix helps you select the most appropriate formats depending on antigen type, desired format, timeline, developability constraints and downstream application.
| Format | Best for | ProteoGenix advantage | Timeline |
|---|---|---|---|
| Bispecific antibody production service | Immune cell engagement, dual-target MOA | IgG-like & fragment formats; nanomolar leads | 8 weeks |
| CAR-T cell development services | Cell-surface targets, adoptive cell therapy | Up to 10 binder sequences, full IP ownership | 10 weeks |
| Single domain antibody service | Difficult epitopes, advances IO applications | 3 binders guaranteed from 1.51 × 10¹⁰ library | 7 weeks |
| Antibody drug conjugate service | Tumor internalization, payload delivery | >90% DAR homogeneity, full ADC characterization | 3 weeks |
Why ProteoGenix?
Proteogenix – a complete scientific partner for oncology antibody development
Immuno-oncology antibody programs are rarely straightforward. Targets can be poorly immunogenic, intracellular, conformational, membrane-bound, rare or highly similar to healthy tissue antigens.
ProteoGenix brings together antigen design, custom antibody discovery, sequencing, engineering, AI-assisted optimization, wet-lab validation and recombinant production to help you move from complex cancer biology to stronger antibody candidates.
-
+25
years of experienceMore than two decades of scientific expertise in antibody discovery, engineering and production.
-
+970
antibodies in preclinical and clinical developmentA proven track record supporting therapeutic antibody programs from early discovery to development.
-
+250
antibodies patentedStrong antibody assets generated for programs requiring sequence ownership and IP-driven development.
Trusted by our clients worldwide
-
We have been working with ProteoGenix since 2023 on the discovery of a VHH targeting a highly challenging surface protein. Using their proprietary LiAb-VHHMAX™ library, they successfully identified 4 specific binders which demonstrated specific target binding with no detectable off-targets. Working hand-in-hand, we continued our partnership on epitope mapping to identify the exact binding site, and ProteoGenix also determined the dissociation constant (KD), which perfectly matched our desired affinity range. Throughout the process, ProteoGenix’s extensive experience and scientific expertise have been invaluable. Their professional guidance and thoughtful advices helped us make the right strategic choices and advance our project efficiently and confidently.
Hadassah Medical Center, Israel
-
We partnered with ProteoGenix for a VHH phage display campaign targeting BCMA, including flow cytometry-based validation of the selected binders. The team quickly delivered high-quality, specific candidates that met our expectations for downstream CAR-T development. We particularly appreciated ProteoGenix’s scientific expertise, as well as their communication and responsiveness, and ability to support a complex discovery project from screening to functional validation.
Karlo Perica, MD, PhD. Memorial Sloan Kettering Cancer Centre
Resource center
Case reports and other resources
-
CAR-T Cell development
130 Validated Antibody Candidates in 3 Weeks Powering CAR-T Therapy for Breast Cancer.
Screening 480 phage binders yielded 130 distinct antibody sequences, all re-validated by monoclonal phage ELISA, delivered to the client in just 3 weeks.
-
Single domain antibody production
Accelerating early-stage discovery of PD-1-targeting VHH candidates for non-small cell lung cancer research.
ProteoGenix delivered 14 unique PD-1-binding VHH sequences (versus the 3 guaranteed) in 3 weeks, of which 10 bound PD-1-expressing cells and 5 showed blocking activity.
-
Bispecific antibody development
Engineering Seven Bispecific Antibody Formats Yielding Nanomolar Leads Against Prostate Cancer.
Seven bispecific formats were designed and expressed against two prostate cancer targets, with three top candidates retaining nanomolar dual-antigen affinity — the best reaching 3.2×10⁻¹⁰ M.
-
Anti-drug conjugate antibody
Helping an Australian university advance ovarian cancer proof-of-concept studies with a characterized ADC.
ProteoGenix delivered over 6 mg of a site-specifically conjugated human IgG1–Vc-MMAE ADC with an average DAR of 3.8 and 92.2% monomeric purity, giving the academic team a fully characterized batch for preclinical proof-of-concept.
-
Complex targets
Rapid Discovery of Selective Anti-pHLA Antibodies for CAR-T Cell Therapy in Melanoma.
By screening three proprietary libraries (>2×10¹¹ clones) in 3 weeks, ProteoGenix identified 4 highly selective anti-pHLA antibodies, one of which was engineered into a CAR-T construct validated in preclinical assays.
-
Focus on immuno-oncology
Is your anticancer therapeutic antibody ready for the next step? Download our dynamic and interactive checklist to thoroughly assess your antibody’s readiness across general criteria and specialized formats. Download now
Upcoming webinar: Join us this September for an upcoming webinar exploring key advances and applications in immuno-oncology. See our webinars
Ready to de-risk your immuno-oncology antibody program?
Whether you are targeting a membrane protein, a peptide-MHC complex, a neoantigen or a tumor-associated antigen, ProteoGenix can help you select the right discovery strategy, engineer the right therapeutic format and move your candidate toward production readiness.
Frequently asked questions about immuno-oncology antibody
